Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07543965

Cohort of Repeat Donor Experiences (CORE) Study

The Plasma Protein Therapeutics Association (PPTA) sponsors the Cohort of Repeat Donor Experiences (CORE) Study. This is a prospective, observational cohort study that will follow Source Plasma donors for up to 2 years during the main study (anticipated to begin in summer 2026) and up to 3 months during the pilot launching in mid-March 2026. This study aims to confirm a lack of negative health effects Source Plasma donors may experience as a result of frequent plasmapheresis. The study will use data obtained through self-report surveys for the duration of the study along with periodic whole blood sample collections to test for CRP, ferritin, and IgG.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–74 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The study employs a two-phase prospective design: (1) data collected before and 48-72 hours after an initial plasma Data will be collected through electronic surveys, real-time illness reports, biomarker analyses, and extracts of Blood Establishment Computer Software (BECS) records including donor screening and operational collection processing variables, if available. Study staff (Study Coordinators employed by the plasma collection companies and Westat central study staff) will engage with participants directly and Westat systems will be used for data collection. The pilot study is planned to occur prior to the main study, planned for early 2026, which will validate the feasibility of study methods and generate preliminary data toward the study aims. The pilot study will involve recruitment and enrollment of 50-90 participants at 2 donor centers for a three-month follow-up period. Pilot study participants will follow the main protocol study procedures, with the addition of brief feedback questions about their participant experience and the omission of End of Year Surveys, due to the shorter follow-up time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-74;
  • Meet health and medical history requirements for being a plasma donor per eCFR::21 CFR 630.10 Subpart B -- General donor eligibility requirements;
  • Willing to provide phone number and mailing address; has access to internet-enabled smartphone device;
  • Plans to remain within local area during study duration; has not donated whole blood within past 12 months;
  • Does not have permanent deferral;
  • Has not donated plasma more than once at a non-participating plasma center;
  • Another member of their household is not enrolled.

Treatment and study plan

Plasmapheresis Procedure

Procedure

Both pilot and main cohort will undergo plasmapheresis (plasma donation) as part of their initial visit for the study. Some participants will donate plasma throughout the duration of either cohort (3 months in pilot or up to 2 years in the main study.

Primary outcomes

  1. Biomarkers

    Time frame: Baseline and every 8 weeks up to 24 months

    To investigate the direct effects of the frequency, recency, and volume of plasmapheresis on biochemical markers and evaluate their role as mediators in the relationship between plasmapheresis and health outcomes.

  2. Short-Term Effects

    Time frame: Baseline and 48 hours following baseline

    To evaluate the short-term effects of plasmapheresis such as post-donation symptoms and functional impairments (e.g., fatigue, subjective health), including issues noted during the collection process, and their associations with subsequent donation behavior.

Secondary outcomes

  1. Cumulative Health

    Time frame: Baseline and every 4 weeks up to 24 months

    To assess the medium- and long-term effects of frequent plasmapheresis on cumulative fatigue, subjective health, and risk of acute illness.

  2. Donation Practices

    Time frame: Baseline through withdrawal

    To investigate risk factors associated with lapses and discontinuation of plasmapheresis.

Study contacts

Contact information is provided by the study sponsor or research team.

Holly Sawyer

CONTACT

[email protected]

706-825-7703

Kathy Chapman

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Westat

Other

Collaborators

  • Plasma Protein Therapeutics Association

Registry information

Official study title

Associations Between Frequent Plasmapheresis, Biomarkers, and Health Outcomes: A 2-Year National Prospective Cohort Study

Acronym: CORE

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Apr 22, 2026
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.